Selank Side Effects: Where the Preparation Is the Risk

Safety statements are only as good as the machinery that collected them. Several possible sources exist in principle, and they are not equally available for this compound.

The two rows that carry weight are the first and second, and they describe a manufactured medicine used under supervision in one jurisdiction. The row that most articles lean on hardest is the last one, which has no denominator at all.

Selank is a synthetic heptapeptide derived from the endogenous peptide tuftsin, developed in Russia and studied mainly as an anxiolytic. It is registered as a medicine there. Clinical work in humans stands behind that registration, and pretending it does not exist is a straightforward factual error that circulates widely in English-language writing.

The opposite error is just as common. Registration in one country is not equivalent to a Western registration trial, and this compound has none. It holds no authorisation from the FDA, the EMA or the MHRA. A search of a Western registry by name returns records that match the text somewhere and turn out to be studies of unrelated interventions, which is why no trial identifier appears anywhere on this page.

There is a third point that both camps skip. Whatever the Russian record contains, it describes the manufactured medicine produced to a regulated standard. Material bought from a research chemical vendor is not that product. It shares a name, and it carries no enforced manufacturing standard, no reviewed label and no assay unless the buyer commissions one.

Self-report deserves more than a dismissal, because it is what most readers are actually working from.

Its first problem is attribution. Headaches, poor sleep, irritability and low mood occur constantly in people who are taking nothing at all, so an account linking one to a substance is proposing a cause rather than demonstrating it. Without a comparison group there is no way to tell the two apart, and that is the entire reason comparison groups exist.

Its second problem is the denominator. A dozen posts describing an effect tell you nothing until you know how many people used the same preparation and said nothing, and that number is unknowable on a forum. Posts are not a sample of what happened; they are a sample of what someone thought worth writing.

Its third problem is specific to this compound and to this site's subject. The preparation behind each account is undocumented. Two people reporting the same effect may have delivered masses differing by a factor of several, for the reasons the next section works out. Pooling their reports produces a list attached to no exposure at all.

None of that makes individual accounts worthless as a prompt to look further. It makes them unusable as a safety profile, which is the job they are usually being asked to do.

Two errors are worth working through, because both are invisible at the point of use.

The fill volume first. Concentration is labelled mass divided by liquid volume. A 5 mg vial intended for 2.5 mL gives 2 mg per mL, and a 0.1 mL event carries 200 mcg. Add 1.8 mL by mistake and the concentration is 5 divided by 1.8, which is 2.78 mg per mL, so the same 0.1 mL now carries 278 mcg, nearly forty per cent more. The syringe still reads 10 units. The pump still clicks once.

The device second. A U-100 syringe makes one unit 0.01 mL; a U-40 makes it 0.025 mL. Reading a U-100 figure off a U-40 barrel multiplies the volume by 2.5. On the spray side the equivalent unknown is the pump rating, and it is worse, because a barrel can at least be inspected while a pump cannot. A bottle at 1 mg per mL delivers 100 mcg through a 0.1 mL pump and 50 mcg through a 0.05 mL pump, and the two bottles look identical.

Stack a fill volume error on an unknown device and the combined uncertainty runs to a factor of several. That is larger than most of the differences people argue about in benefit terms.

Three risks sit entirely outside these calculations, and naming them is more useful than another table.

Sterility is the first. It is a property of technique, of the diluent and of the container, not of a concentration. A calculation reports a clean 200 mcg regardless of what else is in the liquid.

Identity is the second. Nothing about a powder confirms it is the labelled compound, or that it is only that. Assay answers this; arithmetic takes the label as an input and trusts it without question, which means every figure on this page inherits whatever error the label carries.

Degradation is the third. Material in solution is less stable than sealed lyophilised powder, and the loss is neither visible nor linear. A concentration computed on the day of reconstitution is quoted for weeks afterwards as though the container had not changed, because nobody measured the decline.

Put together, the defensible summary is short. There is clinical experience in humans in one country behind a registered medicine, and there is animal work in rats and mice. There is no Western trial, no Western label, and no surveillance stream. The material most English-speaking buyers hold is not the registered product.

Within that, the variables a buyer actually controls are the ones this page has quantified: the labelled mass they were sold, the liquid volume they added, the device they used and the volume it delivers. Those four decide what leaves the container. They decide nothing about what happens next, and no amount of decimal places will make them appear to.